These findings link mutations in the KRAS proto-oncogene to the development of pancreatic cancer and place the downstream ERK and AKT signaling pathways as potential therapeutic targets for the development of pharmacologic inhibitors for the treatment of PDAC [5]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.